Esmaeili Anvar, Nazanin http://orcid.org/0000-0001-7672-8178
Lin, Chenchu
Ma, Xingdi
Wilson, Lori L.
Steger, Ryan
Sangree, Annabel K.
Colic, Medina
Wang, Sidney H.
Doench, John G. http://orcid.org/0000-0002-3707-9889
Hart, Traver http://orcid.org/0000-0002-1880-3341
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM130119)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA275886)
Cancer Prevention and Research Institute of Texas (RP210173, RP210073.)
Article History
Received: 22 September 2023
Accepted: 12 April 2024
First Online: 27 April 2024
Competing interests
: J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo, and Pfizer. J.G.D. consults for and has equity in Tango Therapeutics. J.G.D. serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GlaxoSmithKline. J.G.D. receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology. J.G.D.’s interests were reviewed and are managed by the Broad Institute in accordance with its conflict of interest policies. Other authors don’t claim competing interests.